Home LiteratureArticle Details
PMID: 7042170 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Clinical pharmacokinetics ·Vol. 7 ·No. 1 ·1982-00-00 ·Pages 1-22

Eichelbaum M

Abstract

暂无摘要

MeSH Terms
Amobarbital/metabolism Biological Availability Debrisoquin/metabolism Drug Therapy Drug-Related Side Effects and Adverse Reactions Humans Kinetics Molecular Biology Oxidation-Reduction Pharmaceutical Preparations/metabolism Phenytoin/metabolism Sparteine/metabolism Stereoisomerism Tolbutamide/metabolism
Chemicals
Pharmaceutical Preparations Sparteine Phenytoin Tolbutamide Amobarbital Debrisoquin
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Eichelbaum M
References (54)
54 references, click to expand
  1. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
    Eur J Clin Pharmacol. 1979 Sep;16(3):183-7 PMID: 499318
  2. Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus.
    Br Med J. 1978 Jan 21;1(6106):142-4 PMID: 620227
  3. Coronary care for myocardial infarction in diabetics.
    Lancet. 1974 Mar 23;1(7856):475-7 PMID: 4131883
  4. Pharmacogenetics: multiple interactions between genes and environment as determinants of drug response.
    Am J Med. 1979 Feb;66(2):183-7 PMID: 425962
  5. Comparative metabolism of benzo[a]pyrene and drugs in human liver.
    Clin Pharmacol Ther. 1977 Feb;21(2):166-76 PMID: 837635
  6. Inheritance of phenytoin hypometabolism: a kinetic study of one family.
    Clin Pharmacol Ther. 1980 Jan;27(1):96-103 PMID: 7351122
  7. Polymorphism of carbon oxidation of drugs and clinical implications.
    Br Med J. 1978 Sep 2;2(6138):655-7 PMID: 151576
  8. THE PHYSIOLOGICAL BASIS OF CARDIAC ARRHYTHMIAS.
    Am J Med. 1964 Nov;37:670-84 PMID: 14242077
  9. A method for studying drug metabolism in populations: racial differences in amobarbital metabolism.
    Clin Pharmacol Ther. 1979 Dec;26(6):766-76 PMID: 498719
  10. Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation.
    J Pharm Pharmacol. 1979 May;31(5):350-2 PMID: 37314
  11. The effect of sulfonylurea drugs on rabbit myocardial contractility, canine purkinje fiber automaticity, and adenyl cyclase activity from rabbit and human hearts.
    J Clin Invest. 1972 Sep;51(9):2429-34 PMID: 4344732
  12. Polymorphic hydroxylation of debrisoquine.
    Lancet. 1977 Oct 1;2(8040):718 PMID: 71525
  13. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.
    Drug Metab Dispos. 1975 Sep-Oct;3(5):332-7 PMID: 241613
  14. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
    Drug Metab Rev. 1979;9(2):301-17 PMID: 158499
  15. In vitro metabolism and activation of carcinogenic aromatic amines by subcellular fractions of human liver.
    Cancer Res. 1979 Oct;39(10):4206-11 PMID: 476655
  16. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
    Life Sci. 1980 Nov 3;27(18):1673-7 PMID: 7442467
  17. Long-term tolbutamide treatment after myocardial infarction. A clinical and biochemical study of 178 patients without overt diabetes.
    Acta Med Scand Suppl. 1970;507:1-82 PMID: 4948308
  18. Metabolism of debrisoquine sulphate in rat, dog and man.
    Xenobiotica. 1976 Jul;6(7):405-9 PMID: 997588
  19. Influence of the defective metabolism of sparteine on its pharmacokinetics.
    Eur J Clin Pharmacol. 1979 Sep;16(3):189-94 PMID: 499319
  20. The fate of acetophenetidin in man and methods for the estimation of acetophenetidin and its metabolites in biological material.
    J Pharmacol Exp Ther. 1949 Sep;97(1):58-67 PMID: 18140117
  21. Acetophenetidin-induced methemoglobinemia.
    Ann N Y Acad Sci. 1968 Jul 31;151(2):822-32 PMID: 5263690
  22. Effects of environmental chemicals on the genetic regulation of microsomal enzyme systems.
    Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):640-58 PMID: 71964
  23. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.
    Diabetes. 1970;19:Suppl:789-830 PMID: 4926376
  24. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Eur J Clin Pharmacol. 1980 Feb;17(2):153-5 PMID: 7371707
  25. Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations.
    J Med Genet. 1971 Jun;8(2):129-35 PMID: 5096533
  26. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Clin Pharmacol Ther. 1979 Nov;26(5):584-91 PMID: 498701
  27. Multiple forms of cytochrome P450 in the microsomal monooxygenase system.
    Arch Toxicol. 1977 Dec 30;39(1-2):41-50 PMID: 579981
  28. Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: a study in twins.
    Eur J Clin Pharmacol. 1973 Jun;6(1):44-53 PMID: 4797180
  29. Sparteine sulfate: a potent, capricious oxytocic.
    Am J Obstet Gynecol. 1966 Jan 15;94(2):234-41 PMID: 5900660
  30. [Polymorphisms and deficient drug metabolism as triggers of toxic reactions (author's transl)].
    Arzneimittelforschung. 1977;27(96):1836-44 PMID: 579150
  31. Genetic impairment of phenformin metabolism.
    Lancet. 1980 May 24;1(8178):1147 PMID: 6103491
  32. The disposition of debrisoquine in hypertensive patients.
    Br J Clin Pharmacol. 1978 Jan;5(1):27-34 PMID: 619932
  33. Pharmacogenetics of tolbutamide metabolism in humans.
    Diabetes. 1979 Jan;28(1):41-51 PMID: 569611
  34. Genetic variations in the acetylation of isoniazid and other drugs.
    Ann N Y Acad Sci. 1968 Jul 31;151(2):723-33 PMID: 5263687
  35. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
    J Med Genet. 1980 Apr;17(2):102-5 PMID: 7381862
  36. A case of deficiency of N-hydroxylation of amobarbital.
    Clin Pharmacol Ther. 1977 May;21(5):530-5 PMID: 558078
  37. Hypotensive response to debrisoquine and hydroxylation phenotype.
    Life Sci. 1978 Mar;22(11):979-83 PMID: 642709
  38. Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings].
    Br J Pharmacol. 1979 Jul;66(3):430P-431P PMID: 526719
  39. Genetic control of drug levels in man: antipyrine.
    Science. 1968 Jul 5;161(3836):72-3 PMID: 5690279
  40. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds.
    Life Sci. 1967 Sep 1;6(17):1895-903 PMID: 6052684
  41. Polymorphic hydroxylation of Debrisoquine in man.
    Lancet. 1977 Sep 17;2(8038):584-6 PMID: 71400
  42. Tolbutamide, smoking, and cardiac arrhythmia. A case report.
    JAMA. 1980 Aug 22-29;244(8):811-2 PMID: 6156246
  43. Deficient metabolism of debrisoquine and sparteine.
    Clin Pharmacol Ther. 1980 Apr;27(4):547-9 PMID: 7357813
  44. Drugs, genes and methemoglobinemia.
    Blut. 1977 May;34(5):419-21 PMID: 871540
  45. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians.
    Xenobiotica. 1979 Jan;9(1):51-6 PMID: 760321
  46. INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY.
    Neurology. 1964 Jun;14:542-8 PMID: 14161752
  47. Genetic and environmental factors affecting drug disposition in man.
    Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):659-79 PMID: 334437
  48. Tolbutamide pharmacogenetics and the UGDP controversy.
    JAMA. 1979 Jul 6;242(1):45-8 PMID: 448864
  49. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy.
    Br Med J. 1969 Dec 27;4(5686):764-8 PMID: 5391106
  50. Pharmacogenetics. Report of a WHO scientific group.
    World Health Organ Tech Rep Ser. 1973;524:1-40 PMID: 4196604
  51. Why hypertensive patients vary in their response to oral debrisoquine.
    Br Med J. 1977 Feb 12;1(6058):422-5 PMID: 837136
  52. Sideroblastic anemia in chronic phenacetin misuse.
    Clin Toxicol. 1973;6(4):585-98 PMID: 4790682
  53. The metabolism of [14C]-debrisoquine in man.
    Br J Clin Pharmacol. 1979 Mar;7(3):257-66 PMID: 371651
  54. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy.
    Eur J Clin Pharmacol. 1978 Nov 27;14(3):195-201 PMID: 729614
Article Info
Journal
Clinical pharmacokinetics
Abbr.
Clin Pharmacokinet
ISSN
0312-5963
DOI
10.2165/00003088-198207010-00001
Published
1982-00-00
Pages
1-22
Language
English
Region
Switzerland
NLM ID
7606849
Subset
IM
External Links
PubMed source DOI: 10.2165/00003088-198207010-00001 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2